Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
JCR Pharmaceuticals Co Ltd banner
J

JCR Pharmaceuticals Co Ltd
TSE:4552

Watchlist Manager
JCR Pharmaceuticals Co Ltd
TSE:4552
Watchlist
Price: 516 JPY 0.19% Market Closed
Market Cap: ¥66.9B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
JCR Pharmaceuticals Co Ltd

Wall Street analysts forecast JCR Pharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JCR Pharmaceuticals Co Ltd is 550.8 JPY with a low forecast of 454.5 JPY and a high forecast of 945 JPY.

Lowest Forecast
Wall Street Target
¥454.5
-12% Downside
Average Forecast
Wall Street Target
¥550.8
7% Upside
Highest Forecast
Wall Street Target
¥945
83% Upside
Lowest Forecast
Price Target
454.5 JPY
12% Downside
Average Forecast
Price Target
550.8 JPY
7% Upside
Highest Forecast
Price Target
945 JPY
83% Upside
JCR Pharmaceuticals Co Ltd Competitors:
Price Targets

Revenue
Forecast

8% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
8% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 3%.

What are analyst estimates?

Gross Profit
Forecast

10% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
10% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 3 years is 3%.

What are analyst estimates?

Operating Income
Forecast

-7% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-7% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for JCR Pharmaceuticals Co Ltd

Pre-Tax Income
Forecast

9% / Year
Past Growth
200% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
9% / Year
Past Growth
200% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 9%. The projected CAGR for the next 3 years is 200%.

What are analyst estimates?

Net Income
Forecast

9% / Year
Past Growth
212% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
212% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 212%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other JCR Pharmaceuticals Co Ltd listings:
OTC • USD
JCRRF
 F • EUR
JCR
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is JCR Pharmaceuticals Co Ltd's stock price target?
Price Target
550.8 JPY

According to Wall Street analysts, the average 1-year price target for JCR Pharmaceuticals Co Ltd is 550.8 JPY with a low forecast of 454.5 JPY and a high forecast of 945 JPY.

What is the Revenue forecast for JCR Pharmaceuticals Co Ltd?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 3%.

What is the Gross Profit forecast for JCR Pharmaceuticals Co Ltd?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 3 years is 3%.

What is the Pre-Tax Income forecast for JCR Pharmaceuticals Co Ltd?
Projected CAGR
200%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 9%. The projected CAGR for the next 3 years is 200%.

What is the Net Income forecast for JCR Pharmaceuticals Co Ltd?
Projected CAGR
212%

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 212%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.